AI assistant
ENDRA Life Sciences Inc. — Director's Dealing 2023
May 3, 2023
35444_dirs_2023-05-03_423e2015-2528-4a21-ad03-9d0348f9569a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2023-05-02
Reporting Person: DIGIANDOMENICO ANTHONY (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-02 | Common Stock | P | 83333 | $1.20 | Acquired | 102434 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-05-02 | Warrants | $1.40 | P | 41667 | Acquired | 2028-05-02 | Common Stock (41667) | Direct |
Footnotes
F1: Represents shares purchased in the Registrant's underwritten public offering that closed May 2, 2023 (the "Offering").
F2: The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering.
F3: Represents warrants purchased in the Offering. The warrants were offered and sold at the rate of one warrant to purchase one share for every two shares of common stock purchased in the Offering.